China SXT Pharmaceuticals, Inc. income statement

In fiscal 2026, China SXT Pharmaceuticals, Inc. reported revenue of $1.1m, down 34.6% on the year before, operating income of −$7.1m (a -625.9% margin) and net income of −$6.2m, or −$9.13 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

China SXT Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Revenue	5	7	7	5	5	3	2	2	2	1
Cost of revenue	3	4	2	2	2	1	2	1	1	1
Gross profit	2	3	5	3	3	1	0	1	0	0
Research and development	—	—	—	—	—	0	0	0	—	—
Selling and marketing	—	—	—	—	2	1	0	0	0	0
General and administrative	1	1	1	2	3	6	6	3	3	7
Operating income	2	2	2	−1	−2	−5	−6	−3	−3	−7
Interest expense	0	0	0	3	2	0	0	1	1	0
Income before tax	2	2	2	−10	−3	−5	−6	−3	−3	−6
Income tax	0	0	0	−0	−0	0	—	—	—	—
Net income	1	1	2	−10	−3	−6	−6	−3	−3	−6
Diluted EPS	$885.00	$885.00	$1125.00	$6240.00	−$14321.25	−$20687.70	−$26675.55	−$4285.66	−$348.17	−$9.13
Diluted shares (average)	—	—	—	—	—	—	—	—	—	—
EBITDA	2	2	2	−1	−2	−5	−5	−2	−3	−7

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SXTC vs SXTP LPCN vs SXTC SCNX vs SXTC NTRB vs SXTC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from China SXT Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to China SXT Pharmaceuticals, Inc.